ACCE, Pharmacogenomics, and Stopping Clinical Trials: Time to Extend the CONSORT Statement?

Özdemir, Vural; Joly, Yann; Knoppers, Bartha Maria

doi:10.1080/15265161.2010.546477

Search citation statements

Order By: Relevance

Paper Sections

Select...

Pharmacogenomic Methodologies1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2012

2013

Publication Types

Select...

Book2

Article1

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are now discussions in the literature about how modifications of the CONSORT guidelines could help with the presentation of pharmacogenomic data 47. There are also guidelines on the publication of genetic association studies 48…”

Section: Pharmacogenomic Methodologiesmentioning

confidence: 99%

Paediatric pharmacogenomics: an overview

Hawcutt

Thompson

Smyth³

et al. 2012

Archives of Disease in Childhood

View full text Add to dashboard Cite

Pharmacogenomics research is becoming more prevalent in both academia and the pharmaceutical industry. While some discoveries have been integrated into practice and are benefiting patient care, these successes have been limited given the vast amount of research undertaken. However, the advances in high-throughput genomic technologies, better study designs and improved understanding of complexity, means that pharmacogenomic determinants of drug response will continue to be identified. It is important to develop an understanding of the basis of pharmacogenomics in clinical teams to allow accurate interpretation of the findings, and facilitate their implementation into clinical care (if appropriate). This article explains the science behind pharmacogenomics, and describes some of the challenges that have been encountered in the field, with a specific focus on paediatrics.

show abstract

Section: Pharmacogenomic Methodologiesmentioning

confidence: 99%